HCM

HUTCHMED (China) Limited American Depositary Shares

HCM
Closed
$10.85
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,796 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Country

HK

CEO

Dr. Weiguo Su

IPO date

2006

Employees

1,796

ISIN

KYG4672N1198

Key stats

Open

$11.03

Volume

24.49K

Market cap

$15.54B

Prev. close

$10.98

Impl / hst vl

-

Open interest

$0.00

$10.85

Day’s Range

$11.18

$9.77

52W Range

$16.33

Valuation

61
Valuation score
Undervalued
P/E
-
P/S
-
P/B
1.60
Current ratio
4.96
Debt / Equity
0.02
ROE
37.04%
Gross margin
37.68%
Income growth
-99.57%
FCF growth
-103.64

Analysts estimates

Consensus rating
Buy

The average rating from top 13 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$20.61
The top 14 analysts forecasts that 12-month price may increase by 89.91%, with a low of $13.74 and a high of $27.83
$13.74
Low
$20.61
Avg
$27.83
High
Current price

Earnings

Q4 ‘25 revenue
$270.84M
Q4 ‘25 net income
$1.96M
Revenue
Net income
Previous EPS
-
Estimate EPS
$0.00
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply